Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
AAM Speaks Out Against Build Back Better Bill
US Pricing Policy Could Unfairly Penalize Generics And Biosimilars Manufacturers
Nov 23 2021
•
By
Chloe Kent
Biden's Build Back Better Bill Has Been Criticized By The AAM • Source: Alamy
More from Policy & Regulation
More from Generics Bulletin
